ライフサイエンスコーパス: scleritis

1 are, following published recommendations for scleritis.

2 rily dictate a diagnosis of VKH or posterior scleritis.

3 complications of this subset of patient with scleritis.

4 ve medications were studied in patients with scleritis.

5 Here, we reported 2 cases of M. haemophilum scleritis.

6 eptides may be useful in treating uveitis or scleritis.

7 tion, known as Th-17, has been implicated in scleritis.

8 n for nonnecrotizing, noninfectious anterior scleritis.

9 tis and other forms of optic neuropathy, and scleritis.

10 and 0.052% of patients with Lyme disease had scleritis.

11 nd higher risk of non-infectious uveitis and scleritis.

12 ients in TriNetX, 41,435 were diagnosed with scleritis.

13 patients with an autoimmune condition having scleritis.

14 majority of eyes (66%) had diffuse anterior scleritis.

15 ous, trauma-related, or drug-induced uveitis/scleritis.

16 e primary outcome was clinical resolution of scleritis.

17 ine climate, with concurrence of necrotising scleritis.

18 had the highest relative risk of developing scleritis.

19 in the treatment of non-necrotizing anterior scleritis.

20 to diagnosis and monitoring of patients with scleritis.

21 ale with rheumatoid arthritis presented with scleritis.

22 e for episcleritis and 48.8 years of age for scleritis.

23 west medications associated with uveitis and scleritis.

24 and then compared with those with idiopathic scleritis.

25 diagnosed with episcleritis, 2 with anterior scleritis, 2 with acute macular neuroretinopathy, 1 with

26 cluded anterior uveitis (80.0%) and anterior scleritis (20.0%).

27 Median time-to-remission of scleritis=3.1 years (95% confidence interval (CI): 2.6,

28 ficantly greater in herpetic than idiopathic scleritis (34.3% vs 11.5%; P<0.001).

29 ectronic health records of 500 patients with scleritis, 35 of whom were diagnosed with herpes virus i

30 diagnosed ophthalmologic manifestations were scleritis (36%), retro-orbital pseudotumor or orbital ma

31 Of 500 patients with scleritis, 47 (9.4%) had an underlying infectious cause.

32 osterior uveitis (1%), panuveitis (35%), and scleritis (5%).

33 statistically significant (P = 0.33) between scleritis (60%) and orbital disease (41%).

34 Median time-to-remission of scleritis = 7.8 years (95% confidence interval [CI]: 5.7

35 ilaterality was also more common in herpetic scleritis (80%) than in idiopathic disease (56.7%; P<0.0

36 n a series of 585 patients, 500 patients had scleritis (85.5%) and 85 patients had episcleritis (14.2

37 At last follow-up, most eyes with scleritis (90.4%) had good visual acuity (better than 20

38 Scleritis, a severe inflammatory condition of the sclera

39 Lyme disease scleritis accounted for 0.6% of all cases of scleritis,

40 cal improvement, with 13 (86.6%) achieving a scleritis activity score of zero at 6 months.

41 utcomes were favorable response (decrease in scleritis activity score) and decrease in steroid depend

42 presence of nodules or necrosis, changes in scleritis activity, intraocular pressure (IOP), number o

43 halmic disorders, including episcleritis and scleritis (adjusted IRR 6.11, P < 0.001) and retinal vas

44 Eighteen patients had anterior scleritis and 12 patients had episcleritis.

45 ients with orbital disease (85% vs. 15% with scleritis and 82% vs. 18% with orbital disease; P = 1.00

46 ectronic health records of 500 patients with scleritis and 85 patients with episcleritis seen at 2 te

47 rm of Rosai-Dorfman disease, presenting with scleritis and anterior uveitis in the left eye, who expe

48 numbers increased during active uveitis and scleritis and decreased following treatment.

49 t the observed clinical features of herpetic scleritis and describe the clinical differences at prese

50 One patient developed infectious scleritis and diplopia resulting from Tenon capsule scar

51 underrepresented racial group among cases of scleritis and episcleritis (P = .006, P = .001).

52 opulation-based estimate of the incidence of scleritis and episcleritis in a diverse population and h

53 The overall incidence rates of scleritis and episcleritis were 4.1 (95% CI: 2.6-6.6) an

54 cted to 129 eyes (1 eye per patient) free of scleritis and hypopyon at the start of AAT, topical cort

55 The association between scleritis and infectious disease may be higher than prev

56 M. haemophilum can cause scleritis and keratitis, even in immunocompenent host.

57 for successful management of M. haemophilum scleritis and keratitis.

58 ut underlying disease presented with nodular scleritis and keratouveitis with multiple radial keraton

59 ecular mechanism of scleral diseases such as scleritis and myopia.

60 icacy of rituximab in treating noninfectious scleritis and other ocular inflammatory diseases.

61 tistically significant between patients with scleritis and patients with orbital disease (85% vs. 15%

62 The intersection of scleritis and systemic inflammatory conditions was asses

63 The EMR was searched for scleritis and systemic inflammatory diagnoses in the pas

64 l in treating active, noninfectious anterior scleritis and that gevokizumab is well tolerated.

65 resentation between patients with idiopathic scleritis and those with herpes infection.

66 ment modality for recalcitrant noninfectious scleritis and, in some, can result in long-term durable

67 scleritis accounted for 0.6% of all cases of scleritis, and 0.052% of patients with Lyme disease had

68 Twenty patients had scleritis, and 17 patients had orbital disease; 86% achi

69 y tuberculosis, 125 with uveitis, and 6 with scleritis, and 34 healthy control subjects) were screene

70 ith a range of 773-1089 mum in patients with scleritis, and 825 mum (SD +/- 85.57) with a range of 71

71 an underlying associated disease, bilateral scleritis, and a longer duration of symptoms at presenta

72 an underlying associated disease, bilateral scleritis, and a longer duration of symptoms at presenta

73 s of optic neuropathies, retinal conditions, scleritis, and herpetic eye disease have also been highl

74 loped scleral necrosis, secondary infectious scleritis, and infectious endophthalmitis.

75 nctivitis sicca, cicatricial conjunctivitis, scleritis, and others) mirror other inflammatory ocular

76 drome, cataracts, glaucoma, episcleritis and scleritis, and retinal vascular occlusion in patients wi

77 drome, cataracts, glaucoma, episcleritis and scleritis, and retinal vascular occlusion in these patie

78 eport their involvement in human uveitis and scleritis, and validate our findings in experimental aut

79 lobal incidence and detailed epidemiology of scleritis are poorly understood due to its heterogeneity

80 iated with these conditions, especially with scleritis, are the connective tissue disorders and syste

81 lled patients with refractory, noninfectious scleritis at 24 weeks, although 7 required reinfusion wi

82 nical records of 104 patients diagnosed with scleritis between 1992 and 2011 at the University Medica

83 dictive of less scleritis remission included scleritis bilaterality (adjusted hazard ratio (aHR)=0.57

84 dictive of less scleritis remission included scleritis bilaterality (adjusted hazard ratio [aHR] = 0.

85 Often linked with systemic diseases, scleritis can be either infectious or noninfectious.

86 Necrotizing scleritis can occur in various conditions, such as syste

87 Of 217,061 eligible patients, 17 incident scleritis cases and 93 incident episcleritis cases were

88 Herpes viruses account for 7% of all scleritis cases and its diagnosis may be challenging whe

89 All scleritis cases were anterior, unilateral, without necro

90 A total of 223 episcleritis cases and 77 scleritis cases were identified.

91 unted for 60.1% of episcleritis and 51.9% of scleritis cases.

92 d by age and low vision and blindness in the scleritis cohort were analyzed from 2014 to 2023.

93 emographics and comorbidities of the TriNetX scleritis cohort were similar to scleritis cohorts in pr

94 the TriNetX scleritis cohort were similar to scleritis cohorts in previous studies.

95 antigen staining were noted in the left eye (scleritis, conjunctivitis, and peri-optic neuritis), bra

96 disease characteristics (laterality, type of scleritis, degree of scleral inflammation, ocular compli

97 g the frequency, prevalence, or incidence of scleritis diagnosed through clinical or imaging techniqu

98 em for patients with systemic autoimmune and scleritis diagnoses to determine the prevalence of both

99 atients with a non-infectious uveitis and/or scleritis diagnosis and no diagnosis of infectious, trau

100 there were 4167 controls with no uveitis or scleritis diagnosis.

101 f inflammation, as measured with a validated scleritis disease grading scale (SGS) and reduction in c

102 Understanding scleritis epidemiology is crucial for enhancing diagnost

103 ing ICD-9 codes alone to capture uveitis and scleritis/episcleritis diagnoses is not sufficient in th

104 Herpes zoster ophthalmicus and scleritis/episcleritis ICD-9 codes had PPVs of 91% (95%

105 ended to elucidate diagnoses for uveitis and scleritis/episcleritis.

106 wide incidence and epidemiological trends of scleritis, examining variations across geographic region

107 hereas 80% of lymphocytes from patients with scleritis failed to induce SOCS1 in response to IL-2.

108 Recurrent PUK with scleritis following alkali burns occurred in 5 male pati

109 ale according to a standardized photographic scleritis grading system by 16 weeks in the study eye co

110 nd 28.5%, respectively), followed by chronic scleritis, granuloma, and chalazion (14.25, 14.25, and 1

111 The mild scleritis group had better outcomes in terms of visual i

112 Eyes with scleritis have a greater risk of developing vision-threa

113 the highest the percentage of patients with scleritis having an autoimmune condition.

114 g scleritis, the percentage of patients with scleritis having an autoimmune condition; the relative r

115 n 18 years who were diagnosed with posterior scleritis in a tertiary referral center.

116 Lyme disease is an uncommon cause of scleritis in endemic areas.

117 d with seronegative spondyloarthropathy, and scleritis in patients requiring immunomodulation in pati

118 After identifying all new-onset cases of scleritis in the database, the proportion of new-onset s

119 The development of scleritis in the setting of autoimmune conditions has be

120 no significant differences between sexes for scleritis incidence (P = .75); 23.4% of scleritis patien

121 However, the overall scleritis incidence rate was higher when compared to the

122 ghlights significant regional differences in scleritis incidence, reflecting variations in medical pr

123 Common features of posterior scleritis include concurrent anterior uveitis, disc swel

124 tors for decrease in vision in patients with scleritis include necrotizing scleritis, posterior scler

125 tors for decrease in vision in patients with scleritis included necrotizing scleritis (odds ratio [OR

126 of 392 patients with noninfectious anterior scleritis included NSAIDs in 144 (36.7%), SAIDs in 29 (7

127 Scleritis is a severe ocular inflammatory disease often

128 Scleritis is associated more often with ocular complicat

129 Necrotizing scleritis is one of the most destructive ocular manifest

130 lications than episcleritis, and necrotizing scleritis is the type of scleritis most often associated

131 take many forms, from orbital pseudotumor to scleritis, keratitis, and retinitis.

132 Mild scleritis/limbitis responsive to topical steroids and or

133 third most common condition associated with scleritis- making up 4.5% of cases.

134 Patients with necrotizing scleritis may respond to IMT, mainly alkylating agents.

135 is, and necrotizing scleritis is the type of scleritis most often associated with ocular complication

136 In general, patients with necrotizing scleritis (n = 15) had a poorer outcome.

137 tures included episcleritis (n = 28, 13.7%), scleritis (n = 28, 13.7%), uveitis (n = 25, 12.3%), and

138 Patients had refractory scleritis (n=3), orbital granulomas causing optic nerve

139 rs in the area for any cases of Lyme disease scleritis, none were identified, and the incidence of Ly

140 Patients with scleritis, ocular cicatricial pemphigoid, and peripheral

141 patients with scleritis included necrotizing scleritis (odds ratio [OR], 6.63; P<0.001), posterior sc

142 nderstanding of the immunopathophysiology of scleritis offers hope for future molecule-specific drug

143 ip between systemic autoimmune disorders and scleritis only in patients referred for rheumatologic or

144 conducted to verify a clinical diagnosis of scleritis or episcleritis.

145 Blood from patients with scleritis or healthy human volunteers was analyzed for S

146 ethal (OR = 17.41, P=0.007), and necrotizing scleritis (OR = 4.73, P = 0.026).

147 (odds ratio [OR], 6.63; P<0.001), posterior scleritis (OR, 2.33; P = 0.042), degree of scleral infla

148 s for corneal complications were presence of scleritis (P < .0001; OR: 8.9) and a diagnosis of second

149 Blacks had the highest incidence of scleritis (P = .004).

150 rred most often in patients with necrotizing scleritis (P<0.0001 for each).

151 Women were overrepresented among scleritis patients (P = .049).

152 for scleritis incidence (P = .75); 23.4% of scleritis patients had an associated systemic disease.

153 oimmune condition; the relative risk (RR) of scleritis patients having a specific autoimmune disorder

154 ilar to prior studies with nearly a third of scleritis patients having an underlying autoimmune diagn

155 Of the 41,435 scleritis patients, the majority were Caucasian (56.6%)

156 This review included 74 studies with 169,871 scleritis patients.

157 patients with scleritis include necrotizing scleritis, posterior scleritis, scleral inflammation of

158 Scleritis preceded systemic disease diagnosis in 38.7% o

159 Most patients with herpetic scleritis presented with acute (85.7%) and unilateral (8

160 n electronic medical record on patients with scleritis presenting to the Wilmer Eye Institute between

161 The prevalence of each autoimmune disorder, scleritis prevalence, the percentage of patients with an

162 nversely, 2702 patients were identified with scleritis (prevalence 0.05%), of which 31.4% had an asso

163 itis and scleritis were assessed, as well as scleritis recurrence rates, treatment, and complications

164 There was a slightly decreased risk of scleritis recurrence with older age at diagnosis (hazard

165 edical charts of patients with noninfectious scleritis refractory to conventional immunomodulatory th

166 Twelve patients with noninfectious scleritis refractory to systemic corticosteroid and >/=1

167 djunctive statin treatment truly can enhance scleritis remission (as suggested here) are needed.

168 ibitor or statin treatment truly can enhance scleritis remission (as suggested here) are needed.

169 Factors predictive of less scleritis remission included scleritis bilaterality (adj

170 Factors predictive of less scleritis remission included scleritis bilaterality (adj

171 Our results suggest scleritis remission occurs in a majority by 3.1 years (l

172 Our results suggest scleritis remission occurs more slowly in anterior scler

173 in 11 of 36 eyes (31%), and moderate/severe scleritis, requiring systemic immunosuppressive therapy,

174 Scleritis resolved with oral nonsteroidal anti-inflammat

175 of genetically decreased 25OHD with uveitis/scleritis risk (odds ratio [OR] = 2.16, 95% CI = 1.01-4.

176 s strongly associated with increased uveitis/scleritis risk (OR = 6.42, 95% CI = 3.19-12.89, P = 1.7

177 low 25-hydroxy Vitamin D (25OHD) on uveitis/scleritis risk were calculated.

178 ntion to mitigate non-infectious uveitis and scleritis risk, and should be explored in a prospective

179 tis include necrotizing scleritis, posterior scleritis, scleral inflammation of more than 2+, anterio

180 of 392 patients with noninfectious anterior scleritis seen at 2 tertiary referral centers and studie

181 Patients with active anterior scleritis showed increased thickness of the sclera and p

182 Incidence of scleritis stratified by age and low vision and blindness

183 with varying yearly incidence and prevalence scleritis subtype rates.

184 Data were collected and analyzed by scleritis subtype: anterior, posterior, scleritis with c

185 fective expression of SOCS1 in patients with scleritis, taken together with SOCS1-mediated protection

186 tis remission occurs more slowly in anterior scleritis than in newly diagnosed anterior uveitis or ch

187 ce of episcleritis and a higher incidence of scleritis than populations in previous studies.

188 nt data regarding the cause and treatment of scleritis that has been identified over the past 36 mont

189 patient subsequently developed noninfectious scleritis that required 3-drug-regimen immunosuppression

190 e association between autoimmune disease and scleritis, the findings are similar to prior studies wit

191 patients with an autoimmune condition having scleritis, the percentage of patients with scleritis hav

192 This is the most extensive study on scleritis to date, providing comparative insights across

193 The follow-up after discontinuation of scleritis treatment was 27.2 +/- 31.8 months.

194 to January 1, 2020, including demographics, scleritis type, presence of nodules or necrosis, changes

195 stemic disease with the anatomic location of scleritis using EMR.

196 rgans including eyes such as conjunctivitis, scleritis, uveitis, and corneal ulcer.

197 ation was observed in 35.8% of patients with scleritis versus 27.1% of episcleritis patients, includi

198 were more frequent overall in patients with scleritis versus in those with episcleritis (45.0% vs. 1

199 more commonly seen in patients with herpetic scleritis versus patients with idiopathic disease (8.6%

200 tis vs inflamed pinguecula (n = 1, 13%), and scleritis vs keratoacanthoma (n = 1, 13%).

201 .5; 95% CI, 4.70-57.9), anterior uveitis and scleritis vs other types (aHR, 2.97; 95% CI, 1.46-6.05;

202 The estimated incidence of Lyme scleritis was 0.2 per 1,000,000 population per year (95%

203 of low vision and blindness in the cohort of scleritis was 1263.6 cases per 100,000 person-years.

204 The most common type of scleritis was diffuse anterior in 80% (n = 28), followed

205 dentified, and the incidence of Lyme disease scleritis was estimated using published U.S. Census data

206 The proportion of Lyme disease cases with scleritis was estimated using the number of cases with L

207 Necrotizing anterior scleritis was more commonly seen in patients with herpet

208 Scleritis was notably associated with systemic diseases

209 Scleritis was unilateral in 6 cases and bilateral in 7 c

210 Incidence rates for episcleritis and scleritis were 15.39 and 5.54 per 100,000 per year, resp

211 ve incidence and 10-year prevalence rates of scleritis were 6.8 cases per 100,000 person-years and 35

212 Patients with herpes-associated scleritis were analyzed as a group and then compared wit

213 and disease associations of episcleritis and scleritis were assessed, as well as scleritis recurrence

214 ns in addition to VKH syndrome and posterior scleritis were associated with increased risk of ERD, in

215 Six cases of Lyme disease scleritis were identified in the 8-year time frame; 1 ad

216 Nine cases of uveitis and 7 cases of scleritis were treated.

217 reating isolated ANCA-associated necrotizing scleritis when initial immunosuppressive treatments are

218 We reviewed all patients with uveitis or scleritis who subsequently developed pulmonary or dissem

219 ta collected from all patients with anterior scleritis who used difluprednate as a single treatment a

220 ssociated with idiopathic diffuse or nodular scleritis with a high degree of scleral inflammation (>2

221 Patients with idiopathic diffuse or nodular scleritis with a high degree of scleral inflammation may

222 ssociated with idiopathic diffuse or nodular scleritis with a low degree of scleral inflammation (</=

223 Patients with idiopathic diffuse or nodular scleritis with a low degree of scleral inflammation or w

224 ive, noninfectious, non-necrotizing anterior scleritis with a scleral inflammatory grade of +1 to +3

225 ay effectively treat non-infectious anterior scleritis with a tolerable side effect profile.

226 h IMT was associated with diffuse or nodular scleritis with associated systemic disease (OR = 1.57, P

227 BRMs was associated with diffuse or nodular scleritis with associated systemic disease (OR = 3.15, P

228 Patients with diffuse or nodular scleritis with associated systemic disease may respond t

229 d by scleritis subtype: anterior, posterior, scleritis with corneal involvement, and scleromalacia pe

230 an with acute anterior bilateral necrotizing scleritis with diffuse areas of necrosis, thinning of th

231 Only 1 case presented with scleritis with keratitis.

232 in the database, the proportion of new-onset scleritis with Lyme disease was calculated.

233 active, autoimmune, non-necrotizing anterior scleritis with scleral inflammatory grade of >/=1+ in at

234 three percent of eyes achieved resolution of scleritis, with a median time of resolution of 6 weeks.

235 .001) and with idiopathic diffuse or nodular scleritis without ocular complications (OR = 3.13, P < 0